• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Novo Nordisk Amps Up Drug Discovery with Gefion AI Supercomputer

by Syed Hamza Sohail 06/11/2025 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know:

–DCAI today announced that Novo Nordisk has become a customer of the Gefion AI supercomputer.

– Through this agreement, Novo Nordisk will gain access to Gefion’s unparalleled computational capabilities to process vast datasets, with a goal of transforming drug discovery and development as well as driving healthcare innovation. 

AI-Powered Supercomputing Alliance to Advance Drug Discovery at Scale

In a landmark multiyear agreement, Novo Nordisk and Gefion have partnered to accelerate pharmaceutical innovation by integrating next-generation AI and high-performance computing. This collaboration combines Novo Nordisk’s deep expertise in drug discovery with Gefion’s advanced NVIDIA DGX SuperPod infrastructure—currently ranked 21st on the Top500 list of the world’s most powerful supercomputers.

The partnership is expected to:

·       Accelerate the development of novel therapies by significantly reducing research timelines

·       Support compute-intensive R&D initiatives across Novo Nordisk’s AI-driven drug discovery pipeline

·       Enable large-scale simulations, model development, and advanced analytics that would otherwise be computationally prohibitive

Gefion’s robust technology stack is built to meet the demands of both academic and industry researchers. Its scalable architecture empowers teams to conduct experiments at unprecedented speed and complexity, positioning it as a cornerstone platform for data-intensive pharmaceutical research.

Novo Nordisk has identified AI as a strategic priority across its value chain. The company has also formed a separate collaboration with NVIDIA to build customized AI models that support early-stage research and discovery. Gefion will serve as a critical enabler of these initiatives by providing the computational power necessary to unlock next-generation scientific insights.

Commenting on the collaboration, Nadia Carlsten, CEO of DCAI, noted: “Working alongside Novo Nordisk, we can use Gefion to redefine what is possible in drug research. With Gefion’s compute power, we aim to address the most complex R&D challenges and accelerate time-to-discovery, ultimately unlocking new possibilities in pharmaceutical innovation.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

 Selecting the Right EMR: A Practical Guide to Streamlining Your Practice and Enhancing Patient Care

Selecting the Right EMR: A Practical Guide to Streamlining Your Practice and Enhancing Patient Care

Featured Interview

Virta Health CEO: GLP-1s Didn’t Kill Weight Watchers, Its Broken Model Did

Most-Read

Health IT Sector Navigates Policy Turbulence with Resilient M&A

Health IT’s New Chapter: IPOs Return, Resilient M&A, Valuations Rise in 1H 2025

PwC Report: US Medical Cost Trend to Remain Elevated at 8.5% in 2026

PwC Report: US Medical Cost Trend to Remain Elevated at 8.5% in 2026

Philips Launches ECG AI Marketplace, Partnering with Anumana to Enhance Cardiac Care with AI-Powered Diagnostics

Philips Launches ECG AI Marketplace, Partnering with Anumana to Enhance Cardiac Care with AI-Powered Diagnostics

WeightWatchers Emerges from Bankruptcy, Launches New Menopause Program

WeightWatchers Emerges from Bankruptcy, Launches New Menopause Program

CMS Finalizes New Interoperability and Prior Authorization Rule

CMS Proposes 2026 Physician Fee Schedule Rule: Boosting Primary Care, Cutting Waste, and Modernizing Payments

Beyond SaaS: How Agent as a Service is Transforming Healthcare Automation

Beyond SaaS: How Agent as a Service is Transforming Healthcare Automation

New Strategies Needed: No Surprises Act and the Challenges for Payors with Provider Data Inaccuracies

Samsung Acquires Xealth to Accelerate Connected Care Vision

Samsung Acquires Xealth to Accelerate Connected Care Vision

AI Dominates Digital Health Investment in First Half of 2025

Rock Health Report: AI Dominates Digital Health Investment in First Half of 2025

Moving Beyond EHRs: What Lies Ahead for Healthcare Digitization?

AI Agents vs. Chatbots: Understanding Agentic AI’s Role in Healthcare

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |